Literature DB >> 15694408

Modulation of osteoclast formation.

Julian M W Quinn1, Matthew T Gillespie.   

Abstract

Osteoclasts are derived following the fusion of precursors of hematopoietic and myelomonocytic origin after appropriate stimulus, such as that afforded by RANKL and M-CSF. Thus the osteoclast can be considered as a specialized type of macrophage, and several of the factors that affect osteoclast formation also have affects upon macrophage differentiation. Inhibitors of osteoclast formation may perturb RANKL or M-CSF signalling or affect other signalling pathways. Several of these inhibitors are discussed with the view of their capacity to influence osteoclast differentiation, but not necessarily their activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15694408     DOI: 10.1016/j.bbrc.2004.11.076

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

1.  Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading.

Authors:  Lidan You; Sara Temiyasathit; Peling Lee; Chi Hyun Kim; Padmaja Tummala; Wei Yao; Wade Kingery; Amanda M Malone; Ronald Y Kwon; Christopher R Jacobs
Journal:  Bone       Date:  2007-09-26       Impact factor: 4.398

2.  Both cell-surface and secreted CSF-1 expressed by tumor cells metastatic to bone can contribute to osteoclast activation.

Authors:  Kader Yagiz; Susan R Rittling
Journal:  Exp Cell Res       Date:  2009-05-08       Impact factor: 3.905

3.  Effects of cyclic tension stress on the apoptosis of osteoclasts in vitro.

Authors:  Fengbo Li; Xiaolei Sun; Bin Zhao; Jianxiong Ma; Yang Zhang; Shuang Li; Yanjun Li; Xinlong Ma
Journal:  Exp Ther Med       Date:  2015-03-09       Impact factor: 2.447

4.  Osteoclast activators are elevated in intervertebral disks with Modic changes among patients operated for herniated nucleus pulposus.

Authors:  Matias Torkki; Marja-Leena Majuri; Henrik Wolff; Tatu Koskelainen; Marianne Haapea; Jaakko Niinimäki; Harri Alenius; Jeffrey Lotz; Jaro Karppinen
Journal:  Eur Spine J       Date:  2015-03-27       Impact factor: 3.134

5.  Dissecting the relationship between high-sensitivity serum C-reactive protein and increased fracture risk: the Rotterdam Study.

Authors:  L Oei; N Campos-Obando; A Dehghan; E H G Oei; L Stolk; J B J van Meurs; A Hofman; A G Uitterlinden; O H Franco; M C Zillikens; F Rivadeneira
Journal:  Osteoporos Int       Date:  2013-12-13       Impact factor: 4.507

6.  Lysophosphatidic acid stimulates osteoclast fusion through OC-STAMP and P2X7 receptor signaling.

Authors:  Young Sun Hwang; Gwang-Taek Ma; Kwang-Kyun Park; Won-Yoon Chung
Journal:  J Bone Miner Metab       Date:  2013-04-27       Impact factor: 2.626

7.  TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation.

Authors:  Betty Lamothe; William K Webster; Ambily Gopinathan; Arnaud Besse; Alejandro D Campos; Bryant G Darnay
Journal:  Biochem Biophys Res Commun       Date:  2007-06-11       Impact factor: 3.575

8.  Influence of receptor activator of nuclear factor (NF)-kappaB ligand (RANKL), macrophage-colony stimulating factor (M-CSF) and fetal calf serum on human osteoclast formation and activity.

Authors:  Ludwika Kreja; Astrid Liedert; Carla Schmidt; Lutz Claes; Anita Ignatius
Journal:  J Mol Histol       Date:  2007-06-19       Impact factor: 2.611

9.  sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.

Authors:  K K Doumouchtsis; A I Kostakis; S K Doumouchtsis; M P Tziamalis; C Tsigris; M A Kostaki; D N Perrea
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

10.  Osteoclast inhibitory lectin, an immune cell product that is required for normal bone physiology in vivo.

Authors:  Vicky Kartsogiannis; Natalie A Sims; Julian M W Quinn; Chi Ly; Mirijana Cipetic; Ingrid J Poulton; Emma C Walker; Hasnawati Saleh; Narelle E McGregor; Morgan E Wallace; Mark J Smyth; T John Martin; Hong Zhou; Kong Wah Ng; Matthew T Gillespie
Journal:  J Biol Chem       Date:  2008-09-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.